Biomarker Discovery for Suicide Precision Circuit Therapeutics | NCT07723066

NCT07723066

Overview

NCT ID: NCT07723066
Lead Sponsor: Massachusetts General HospitalOTHER
Official Title: Biomarker Discovery for Suicide Precision Circuit Therapeutics
Brief Summary: This is a prospective observational biomarker study assessing changes in clinical, behavioral, neuroimaging, and neurophysiological measurer following ketamine/esketamine or electroconvulsive therapy (ECT) in adults with suicidal thoughts or behaviors.
Conditions: Suicidal Thoughts and Behaviors
Major Depressive Episode (MDE)
Interventions: No data available

Status and Timeline

Status: Not yet recruiting
Last Update Posted: Jul 23, 2026Actual
Start Date: Jul 2026Estimated
Primary Completion Date: Jul 2029Estimated
Completion Date

Participation Criteria

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

Adults aged 18 to 65 years

Diagnosis of a major depressive episode associated with Major Depressive Disorder or Bipolar Disorder

Presence of moderate to severe suicidal thoughts or behaviors, as determined by the Beck Scale for Suicide Ideation (BSSI)

Scheduled to receive an acute treatment course of electroconvulsive therapy (ECT), intravenous ketamine, or intranasal esketamine as part of routine clinical care

Ability and willingness to provide informed consent

Exclusion Criteria:

Neurological disorders, particularly conditions associated with known structural brain lesions

Inability to meet MRI safety requirements

Current alcohol dependence

Active symptoms of non-alcohol psychoactive substance withdrawal

Study Plan

Study Type: Observational
Phase: No data available
Enrollment: 60Estimated
Primary Purpose: No data available
Allocation: No data available
Interventional Model: No data available
Masking: No data available

Contacts and Locations

Central Contacts: Joan Camprodon, MD, PhD, MPHContact
JCAMPRODON@mgh.harvard.edu617-726-5340

Similar Studies

Participant Group/Arms

Ketamine/Esketamine

Participants with a major depressive episode and moderate to severe suicidal thoughts or behaviors who are scheduled to receive intravenous ketamine or intranasal esketamine as part of routine clinical care. Treatment is determined by the clinical care team and is not assigned by the study. Participants complete clinical, behavioral, MRI, and EEG assessments before and after treatment.

Electroconvulsive Therapy (ECT)

Participants with a major depressive episode and moderate to severe suicidal thoughts or behaviors who are scheduled to receive an acute course of electroconvulsive therapy (ECT) as part of routine clinical care. Treatment is determined by the clinical care team and is not assigned by the study. Participants complete clinical, behavioral, MRI, and EEG assessments before and after treatment.